Trials / Completed
CompletedNCT04770922
Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia
Pharmacogenomic Analysis of 6-mercaptopurine in Pediatric Acute Lymphoblastic Leukemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (actual)
- Sponsor
- Cipherome, Inc. · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.
Detailed description
The study objective is to clinically validate that the presence of recently discovered novel genetic variation adversely affects a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients using biobank samples.
Conditions
Timeline
- Start date
- 2021-02-23
- Primary completion
- 2021-08-30
- Completion
- 2021-11-10
- First posted
- 2021-02-25
- Last updated
- 2023-02-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04770922. Inclusion in this directory is not an endorsement.